The Manufacturers Life Insurance Company Sells 8,149 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

The Manufacturers Life Insurance Company lowered its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 6.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 117,252 shares of the company’s stock after selling 8,149 shares during the quarter. The Manufacturers Life Insurance Company owned 0.12% of Neurocrine Biosciences worth $13,510,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Tidal Investments LLC raised its position in Neurocrine Biosciences by 57.8% during the 1st quarter. Tidal Investments LLC now owns 9,542 shares of the company’s stock valued at $1,316,000 after purchasing an additional 3,497 shares during the last quarter. Swedbank AB bought a new position in shares of Neurocrine Biosciences during the first quarter valued at approximately $1,933,000. GAMMA Investing LLC lifted its stake in Neurocrine Biosciences by 34.1% in the second quarter. GAMMA Investing LLC now owns 1,553 shares of the company’s stock worth $214,000 after acquiring an additional 395 shares during the period. First Hawaiian Bank boosted its holdings in Neurocrine Biosciences by 6.2% in the second quarter. First Hawaiian Bank now owns 5,483 shares of the company’s stock valued at $755,000 after acquiring an additional 320 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV increased its position in Neurocrine Biosciences by 43.4% during the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 512 shares of the company’s stock valued at $70,000 after purchasing an additional 155 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Jefferies Financial Group lifted their target price on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the company a “buy” rating in a research note on Monday, August 19th. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a report on Monday, November 11th. Raymond James restated an “outperform” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Piper Sandler raised Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $131.00 to $159.00 in a research note on Thursday, August 29th. Finally, JPMorgan Chase & Co. raised their price objective on Neurocrine Biosciences from $173.00 to $181.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Five investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $163.91.

Neurocrine Biosciences Trading Up 0.1 %

Shares of NBIX stock opened at $126.75 on Monday. Neurocrine Biosciences, Inc. has a 12-month low of $110.95 and a 12-month high of $157.98. The stock has a market capitalization of $12.83 billion, a P/E ratio of 33.98 and a beta of 0.35. The firm’s 50 day moving average is $119.26 and its 200 day moving average is $131.48.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.